×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
MPN
Alexandra Guadagno
From today’s top entertainers to racial disparities in access to pain treatment, here’s what is making headlines in the cancer space this week.
Kristie L. Kahl
The Food and Drug Administration granted a fast track designation to momelotinib for the treatment of patients with intermediate/high-risk myelofibrosis who have previously received a JAK inhibitor.
Alexandra Guadagno
The FDA has approved Jakafi, the first and only treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients aged 12 years and older.
Alexandra Guadagno
From World Blood Cancer Day to today’s top performers fundraising for lifesaving research, here’s what’s making headlines in the cancer space this week.
Kristie L. Kahl
Only half of patients reported their blood cancer was detected while visiting a doctor after experiencing symptoms versus detection during a routine medical test or exam or while under the care of a doctor for another health condition.
Jessica Skarzynski
A new analysis of the myMPN Patient Registry has led to some exciting new discoveries, according to researchers.
Beth Fand Incollingo
The U.S. Food and Drug Administration (FDA) will give a priority review to the experimental targeted drug fedratinib as a potential treatment for the blood cancer myelofibrosis.
Jean Diesch
Any action, larger or small, can make a major impact in the lives of patients with a myeloproliferative neoplasm.
Celia Miltz
After her daughter was diagnosed, Celia Miltz founded the Friends of ET Research.
Angela Fleischman, M.D., Ph.D.
Angela Fleischman, M.D., Ph.D., is particularly excited for improvements in treating early-stage disease.